Laryngeal Mass Found in 28-Year-Old Man

Data support the IGG signature, especially its key gene subset, as a potential marker of sustained antitumor activity in breast cancer.

Paolo Tarantino, MD, and Matteo Lambertini, MD, PhD discuss findings related to CDK4/6 inhibitors and antibody drug conjugates presented at SABCS 2024.

In the IGNYTE-ESO trial, letetresgene autoleucel elicited an ORR of 43%, a median PFS of 7.7 months, and a median DOR of 12.2 months in those with MRCLS.

Authors of an article published in ONCOLOGY® detail how a novel multidisciplinary lifestyle medicine clinic can meet the needs of cancer survivors.

Investigators of the phase 3 C-POST trial will continue to follow up with patients and assess the key secondary end point of overall survival.

Investigators are assessing treatment with ELC-100 among patients with pancreatic neuroendocrine tumors as part of a phase 1/2 trial.